Wednesday, June 10, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Islet Cell Transplant Data Presented At ADA Meeting. Eledon presented data at the American Diabetes Association Annual Meeting from its trial testing tegoprubart as an immunosuppressive in patients with Type 1 diabetes (T1D) receiving pancreatic islet cell transplants. These data update earlier presentations with additional patients and longer follow-up periods. After treatment, the patients were able to become insulin independent with no rejection episodes or treatment-related side effects.
Study Design. The trial enrolled 12 patients with Type 1 diabetes and poorly controlled glucose levels. Patients had diabetes for a mean duration of 33 years and a mean HbA1C of 8.0% at baseline. All received allogeneic pancreatic islet cell transplants with tegoprubart as part of their immunosuppression regimen instead of tacrolimus, a calcineurin inhibitor that is the standard of care in transplantation.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.